1. EP-2327: Hypoxic cell killing by CP-506, a novel hypoxia-activated prodrug. (April 2018) Authors: Niemans, R.; Yaromina, A.; Theys, J.; Marcus, D.; Ashoorzadeh, A.; Abbattista, M.; Mowday, A.; Biemans, R.; Lieuwes, N.; Deschoemaeker, S.; Heyerick, A.; Guise, C.; Smaill, J.B.; Patterson, A.V.; Dubois, L.; Lambin, P. Journal: Radiotherapy and oncology Issue: Volume 127(2018)Supplement 1 Page Start: S1283 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. OC-0236: DTP-006: a novel, orally bioavailable hypoxia-activated prodrug. (April 2016) Authors: Niemans, R.; Yaromina, A.; Theys, J.; Ashoorzadeh, A.; Anderson, R.; Bull, M.; Guise, C.; Hsu, H.L.; Abbattista, M.; Mowday, A.; Patterson, A.V.; Smaill, J.B.; Ackerley, D.F.; Dubois, L.; Lambin, P. Journal: Radiotherapy and oncology Issue: Volume 119(2016)Supplement 1 Page Start: S107 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. OC-0562: Exploiting tumor DNA repair status and hypoxia with CP-506, a novel hypoxia-activated prodrug. (November 2020) Authors: Van der Wiel, A.; Marcus, D.; Niemans, R.; Yaromina, A.; Theys, J.; Mowday, A.; Ashoorzadeh, A.; Anderson, R.; Bull, M.; Abbattista, M.; Heyerick, A.; Guise, C.; Smaill, J.; Patterson, A.; Dubois, L.; Lambin, P. Journal: Radiotherapy and oncology Issue: Volume 152(2020)Supplement 1 Page Start: S313 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. OC-0591: Hypoxic cell killing by SN36506, a novel hypoxia-activated prodrug. (May 2017) Authors: Niemans, R.; Yaromina, A.; Theys, J.; Ashoorzadeh, A.; Anderson, R.; Bull, M.; Guise, C.; Hsu, H.L.; Abbattista, M.; Mowday, A.; Patterson, A.V.; Smaill, J.B.; Dubois, L.; Lambin, P. Journal: Radiotherapy and oncology Issue: Volume 123:(2017:May)Supplement 1 Page Start: S311 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
5. PO-1061: Evofosfamide sensitizes esophageal carcinomas to radiation without increasing normal tissue toxicity. (April 2018) Authors: Spiegelberg, L.; Biemans, R.; Lieuwes, N.; Niemans, R.; Theys, J.; Yaromina, A.; Verhaegen, F.; Lambin, P.; Dubois, L. Journal: Radiotherapy and oncology Issue: Volume 127(2018)Supplement 1 Page Start: S595 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗